An Open-Label, Multicenter, Phase 1b/2 Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior VEGF-Targeted Treatment

Trial Profile

An Open-Label, Multicenter, Phase 1b/2 Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior VEGF-Targeted Treatment

Completed
Phase of Trial: Phase I/II

Latest Information Update: 20 Apr 2018

At a glance

  • Drugs Lenvatinib (Primary) ; Everolimus
  • Indications Renal cell carcinoma
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms Study 205
  • Sponsors Eisai Co Ltd
  • Most Recent Events

    • 05 Apr 2018 Status changed to completed.
    • 12 Oct 2017 Results comparing survival differences between crossover non-crossover using networked data from HOPE 205, CHECKMATE-025,TARGET, AXIS, RECORD-1, METEOR studies, presented at the 20th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.
    • 27 Mar 2017 According to an Eisai Co Ltd media release, based on the data from this study, German Federal Joint Committee (G-BA) has confirmed the additional benefit of lenvatinib in combination with everolimus for the treatment of adults with advanced RCC versus everolimus alone.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top